Skip to main content
. 2021 Sep 14;150(1):124–131. doi: 10.1002/ijc.33785

FIGURE 2.

FIGURE 2

The use of CDK4/6 inhibitors in patients diagnosed with HR+/HER2− ABC since August 2017. (A) Cumulative use of CDK4/6 inhibitors since date of ABC diagnosis by competing risk methodology. (B) First‐line treatment choice for all patients (n = 214), and second‐line treatment choice for CDK4/6 inhibitor naïve patients (n = 71). ABC, advanced breast cancer; CDK4/6, cyclin‐dependent kinase 4/6; CDK4/6i, CDK4/6 inhibitors; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor [Color figure can be viewed at wileyonlinelibrary.com]